International randomized, double-blind, placebo-controlled, phase 3 study of linsitinib (OSI-906, L) in patients (pts) with locally advanced or metastatic adrenocortical carcinoma (ACC).

被引：1
|
作者：
Quinn, David I.
Baudin, Eric
Demeure, Michael J.
Fassnacht, Martin
Hammer, Gary D.
Poondru, Srinivasu
Fleege, Tanya
Rorig, Ramona
Berruti, Alfredo
机构：
[1] Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA
[2] Inst Gustave Roussy, Villejuif, France
[3] TGen, Phoenix, AZ USA
[4] Univ Hosp Wuerzburg, Dept Internal Med 1, Endocrine Unit, Wurzburg, Germany
[5] Univ Michigan, Ann Arbor, MI 48109 USA
[6] APGD, Northbrook, IL USA
[7] Astellas Pharma Global Dev, Northbrook, IL USA
[8] Astellas Pharma, Northbrook, IL USA
[9] Univ Brescia, Dept Med & Surg Specialties, Radiol Sci & Publ Hlth, Med Oncol, Brescia, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.4507
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4507
引用
收藏
页数：1
相关论文
共 50 条
  • [21] TERRA: a randomized, double-blind, placebo-controlled phase 3 study of TAS-102 in Asian patients with metastatic colorectal cancer
    Kim, T. W.
    Shen, L.
    Xu, J. M.
    Sriuranpong, V.
    Pan, H.
    Xu, R.
    Han, S-W.
    Liu, T.
    Park, Y. S.
    Shir, C.
    Bai, Y.
    Bi, F.
    Ahn, J. B.
    Qin, S.
    Li, Q.
    Wu, C.
    Zhou, F.
    Ma, D.
    Srimuninnimit, V.
    Li, J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [22] Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial
    Gounder, Mrinal M.
    Razak, Albiruni Abdul
    Somaiah, Neeta
    Chawla, Sant
    Martin-Broto, Javier
    Grignani, Giovanni
    Schuetze, Scott M.
    Vincenzi, Bruno
    Wagner, Andrew J.
    Chmielowski, Bartosz
    Jones, Robin L.
    Riedel, Richard F.
    Stacchiotti, Silvia
    Loggers, Elizabeth T.
    Ganjoo, Kristen N.
    Le Cesne, Axel
    Italiano, Antoine
    Garcia Del Muro, Xavier
    Burgess, Melissa
    Piperno-Neumann, Sophie
    Ryan, Christopher
    Mulcahy, Mary F.
    Forscher, Charles
    Penel, Nicolas
    Okuno, Scott
    Elias, Anthony
    Hartner, Lee
    Philip, Tony
    Alcindor, Thierry
    Kasper, Bernd
    Reichardt, Peter
    Lapeire, Lore
    Blay, Jean-Yves
    Chevreau, Christine
    Valverde Morales, Claudia Maria
    Schwartz, Gary K.
    Chen, James L.
    Deshpande, Hari
    Davis, Elizabeth J.
    Nicholas, Garth
    Groeschel, Stefan
    Hatcher, Helen
    Duffaud, Florence
    Herraez, Antonio Casado
    Diaz Beveridge, Roberto
    Badalamenti, Giuseppe
    Eriksson, Mikael
    Meyer, Christian
    von Mehren, Margaret
    Van Tine, Brian A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (22) : 2479 - +
  • [23] AMG 386 in Combination With Sorafenib in Patients With Metastatic Clear Cell Carcinoma of the Kidney A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study
    Rini, Brian
    Szczylik, Cezary
    Tannir, Nizar M.
    Koralewski, Piotr
    Tomczak, Piotr
    Deptala, Andrzej
    Dirix, Luc Y.
    Fishman, Mayer
    Ramlau, Rodryg
    Ravaud, Alain
    Rogowski, Wojciech
    Kracht, Karolyn
    Sun, Yu-Nien
    Bass, Michael B.
    Puhlmann, Markus
    Escudier, Bernard
    CANCER, 2012, 118 (24) : 6152 - 6161
  • [24] GLANCE Results of a phase 2, randomized, double-blind, placebo-controlled study
    Goodman, A. D.
    Rossman, H.
    Bar-Or, A.
    Miller, A.
    Miller, D. H.
    Schmierer, K.
    Lublin, F.
    Khan, O.
    Bormann, N. M.
    Yang, M.
    Panzara, M. A.
    Sandrock, A. W.
    NEUROLOGY, 2009, 72 (09) : 806 - 812
  • [25] An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis
    Lebwohl, M
    Christophers, E
    Langley, R
    Ortonne, JP
    Roberts, J
    Griffiths, CEM
    ARCHIVES OF DERMATOLOGY, 2003, 139 (06) : 719 - 727
  • [26] RANGE: A randomized, double-blind, placebo-controlled phase 3 study of docetaxel (DOC) with or without ramucirumab (RAM) in platinum-refractory advanced or metastatic urothelial carcinoma
    Petrylak, D. P.
    Chi, K. N.
    Drakaki, A.
    Sternberg, C. N.
    de Wit, R.
    Nishiyama, H.
    Yu, E. Y.
    Castellano, D.
    Hussain, S.
    Percent, I. J.
    Flechon, A.
    Bamias, A.
    Van der Heijden, M. S.
    Matsubara, N.
    Alekseev, B.
    Walgren, R. A.
    Hamid, O.
    Zimmermann, A. H.
    Bell-Mcguinn, K. M.
    Powles, T.
    ANNALS OF ONCOLOGY, 2017, 28
  • [27] SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma
    Zhu, Andrew X.
    Rosmorduc, Olivier
    Evans, T. R. Jeffry
    Ross, Paul J.
    Santoro, Armando
    Carrilho, Flair Jose
    Bruix, Jordi
    Qin, Shukui
    Thuluvath, Paul J.
    Llovet, Josep M.
    Leberre, Marie-Aude
    Jensen, Markus
    Meinhardt, Gerold
    Kang, Yoon-Koo
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (06) : 559 - 566
  • [28] REGENERATE: A Global Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of OCA for NASH
    Ratziu, Vlad
    Sanyal, Arun J.
    MacConell, Leigh
    Herrmann, Sibylle
    Shringarpure, Reshma
    Marmon, Tonya
    Shapiro, David
    Younossi, Zobair M.
    SWISS MEDICAL WEEKLY, 2016, 146 : 17S - 17S
  • [29] Galcanezumab in episodic migraine: the phase 3, randomized, double-blind, placebo-controlled PERSIST study
    Hu, Bo
    Li, Gang
    Li, Xiaohong
    Wu, Shan
    Yu, Tingmin
    Li, Xiang
    Zhao, Hongru
    Jia, Zhihua
    Zhuang, Junpeng
    Yu, Shengyuan
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (01):
  • [30] ROMIPLOSTIM IN CHILDREN WITH IMMUNE THROMBOCYTOPENIA: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
    Tarantino, M.
    Bussel, J.
    Blanchette, V.
    Despotovic, J.
    Bennett, C.
    Raj, A.
    Williams, B.
    Beam, D.
    Morales, J.
    Rose, M.
    Carpenter, N.
    Eisen, M.
    HAEMATOLOGICA, 2016, 101 : 137 - 137
12345